In particular, CDK1 targeting could be a favorable approach for BC treatment, based on the finding that urothelial carcinoma subtypes with a poor prognosis exhibit high expression levels of late cell cycle genes such as CDK1 and the cyclin B complex or genes related to chromosome segregation and cell division39,40. This evidence concerns the gene CDK1 and urothelial carcinoma.